Publication of Form 20-F

RNS Number : 4144H
Hutchison China Meditech Limited
12 March 2018
 

 

 

Press release

 

Publication of Form 20-F

 

 

London: Monday, March 12, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2017.  This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/4144H_1-2018-3-12.pdf and also on the website of the Company at www.chi-med.com.

 

 

About Chi-Med

 

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

 

 

CONTACTS

 

Investor Enquiries



Mark Lee, Senior Vice President, Corporate Finance & Development

+852 2121 8200





U.K. & International Media Enquiries



Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)

anthony.carlisle@cdrconsultancy.co.uk




U.S. Based Media Enquiries



Brad Miles, BMC Communications

+1 (917) 570 7340 (Mobile)

bmiles@bmccommunications.com

Susan Duffy, BMC Communications

+1 (917) 499 8887 (Mobile)

sduffy@bmccommunications.com




Investor Relations



Matt Beck, The Trout Group

+1 (917) 415 1750 (Mobile)

mbeck@troutgroup.com

David Dible, Citigate Dewe Rogerson 

+44 7967 566 919 (Mobile)

david.dible@citigatedewerogerson.com




Panmure Gordon (UK) Limited



Richard Gray / Andrew Potts

+44 (20) 7886 2500


 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFILVFIFLIT
UK 100

Latest directors dealings